Therapy of refractory nontuberculous mycobacterial lung disease

David E. Griffith, Timothy Aksamit

Research output: Contribution to journalReview article

51 Citations (Scopus)

Abstract

PURPOSE OF REVIEW: The prevalence of nontuberculous mycobacterial (NTM) lung disease is increasing in the USA. Clinicians are therefore encountering these patients with increasing frequency, with the attendant multiple therapeutic challenges presented by NTM lung disease including relatively frequent (compared with tuberculosis) treatment failure. RECENT FINDINGS: Critical elements for the successful treatment of Mycobacterium avium complex (MAC) lung disease include aggressive first therapeutic attempts and avoidance of the emergence of macrolide-resistant MAC strains, which are associated with worse treatment response and increased mortality. Reliably effective therapy for M. abscessus lung disease remains elusive but still usually requires parenteral agents. Lung resection surgery for selected patients is an important adjunct for both MAC and M. abscessus lung disease. Aside from surgery and parenteral antibiotics, there are very few data to support the efficacy of other drugs or interventions for patients who have failed the first-line therapy. SUMMARY: Clinicians who manage NTM lung disease will inevitably encounter patients who fail the first-line therapy. The choices for effective treatment of these patients are depressingly sparse. It is critically important to avoid creation of macrolide-resistant MAC strains and to carefully choose those NTM lung disease patients who will benefit from surgery.

Original languageEnglish (US)
Pages (from-to)218-227
Number of pages10
JournalCurrent Opinion in Infectious Diseases
Volume25
Issue number2
DOIs
StatePublished - Apr 2012

Fingerprint

Lung Diseases
Mycobacterium avium Complex
Macrolides
Therapeutics
Treatment Failure
Tuberculosis
Anti-Bacterial Agents
Lung
Mortality
Pharmaceutical Preparations

Keywords

  • Mycobacterium abscessus
  • Mycobacterium avium complex
  • nontuberculous mycobacteria

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

Therapy of refractory nontuberculous mycobacterial lung disease. / Griffith, David E.; Aksamit, Timothy.

In: Current Opinion in Infectious Diseases, Vol. 25, No. 2, 04.2012, p. 218-227.

Research output: Contribution to journalReview article

@article{95d92269fee24e288e99c20e7dd83749,
title = "Therapy of refractory nontuberculous mycobacterial lung disease",
abstract = "PURPOSE OF REVIEW: The prevalence of nontuberculous mycobacterial (NTM) lung disease is increasing in the USA. Clinicians are therefore encountering these patients with increasing frequency, with the attendant multiple therapeutic challenges presented by NTM lung disease including relatively frequent (compared with tuberculosis) treatment failure. RECENT FINDINGS: Critical elements for the successful treatment of Mycobacterium avium complex (MAC) lung disease include aggressive first therapeutic attempts and avoidance of the emergence of macrolide-resistant MAC strains, which are associated with worse treatment response and increased mortality. Reliably effective therapy for M. abscessus lung disease remains elusive but still usually requires parenteral agents. Lung resection surgery for selected patients is an important adjunct for both MAC and M. abscessus lung disease. Aside from surgery and parenteral antibiotics, there are very few data to support the efficacy of other drugs or interventions for patients who have failed the first-line therapy. SUMMARY: Clinicians who manage NTM lung disease will inevitably encounter patients who fail the first-line therapy. The choices for effective treatment of these patients are depressingly sparse. It is critically important to avoid creation of macrolide-resistant MAC strains and to carefully choose those NTM lung disease patients who will benefit from surgery.",
keywords = "Mycobacterium abscessus, Mycobacterium avium complex, nontuberculous mycobacteria",
author = "Griffith, {David E.} and Timothy Aksamit",
year = "2012",
month = "4",
doi = "10.1097/QCO.0b013e3283511a64",
language = "English (US)",
volume = "25",
pages = "218--227",
journal = "Current Opinion in Infectious Diseases",
issn = "0951-7375",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Therapy of refractory nontuberculous mycobacterial lung disease

AU - Griffith, David E.

AU - Aksamit, Timothy

PY - 2012/4

Y1 - 2012/4

N2 - PURPOSE OF REVIEW: The prevalence of nontuberculous mycobacterial (NTM) lung disease is increasing in the USA. Clinicians are therefore encountering these patients with increasing frequency, with the attendant multiple therapeutic challenges presented by NTM lung disease including relatively frequent (compared with tuberculosis) treatment failure. RECENT FINDINGS: Critical elements for the successful treatment of Mycobacterium avium complex (MAC) lung disease include aggressive first therapeutic attempts and avoidance of the emergence of macrolide-resistant MAC strains, which are associated with worse treatment response and increased mortality. Reliably effective therapy for M. abscessus lung disease remains elusive but still usually requires parenteral agents. Lung resection surgery for selected patients is an important adjunct for both MAC and M. abscessus lung disease. Aside from surgery and parenteral antibiotics, there are very few data to support the efficacy of other drugs or interventions for patients who have failed the first-line therapy. SUMMARY: Clinicians who manage NTM lung disease will inevitably encounter patients who fail the first-line therapy. The choices for effective treatment of these patients are depressingly sparse. It is critically important to avoid creation of macrolide-resistant MAC strains and to carefully choose those NTM lung disease patients who will benefit from surgery.

AB - PURPOSE OF REVIEW: The prevalence of nontuberculous mycobacterial (NTM) lung disease is increasing in the USA. Clinicians are therefore encountering these patients with increasing frequency, with the attendant multiple therapeutic challenges presented by NTM lung disease including relatively frequent (compared with tuberculosis) treatment failure. RECENT FINDINGS: Critical elements for the successful treatment of Mycobacterium avium complex (MAC) lung disease include aggressive first therapeutic attempts and avoidance of the emergence of macrolide-resistant MAC strains, which are associated with worse treatment response and increased mortality. Reliably effective therapy for M. abscessus lung disease remains elusive but still usually requires parenteral agents. Lung resection surgery for selected patients is an important adjunct for both MAC and M. abscessus lung disease. Aside from surgery and parenteral antibiotics, there are very few data to support the efficacy of other drugs or interventions for patients who have failed the first-line therapy. SUMMARY: Clinicians who manage NTM lung disease will inevitably encounter patients who fail the first-line therapy. The choices for effective treatment of these patients are depressingly sparse. It is critically important to avoid creation of macrolide-resistant MAC strains and to carefully choose those NTM lung disease patients who will benefit from surgery.

KW - Mycobacterium abscessus

KW - Mycobacterium avium complex

KW - nontuberculous mycobacteria

UR - http://www.scopus.com/inward/record.url?scp=84858009182&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858009182&partnerID=8YFLogxK

U2 - 10.1097/QCO.0b013e3283511a64

DO - 10.1097/QCO.0b013e3283511a64

M3 - Review article

VL - 25

SP - 218

EP - 227

JO - Current Opinion in Infectious Diseases

JF - Current Opinion in Infectious Diseases

SN - 0951-7375

IS - 2

ER -